Catalog No.
DHC15801
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Hybridoma growth factor, BSF-2, IFN-beta-2, CDF, IL6, Interleukin-6, IL-6, B-cell stimulatory factor 2, Interferon beta-2, IFNB2, CTL differentiation factor
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05231
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CLLB8, CNTO 328, CAS: 541502-14-1
Clone ID
Siltuximab
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial, PMID: 25042199
Siltuximab, PMID: 31644237
Siltuximab, PMID: 29999789
Pharmaco-Immunomodulatory Therapy in COVID-19, PMID: 32696108
Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials, PMID: 32027862
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19, PMID: 32499314
Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease, PMID: 29391839
Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease, PMID: 26394632
Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy, PMID: 27049586
Clinical development of siltuximab, PMID: 25986720
Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma, PMID: 28140696
Cytokine storm intervention in the early stages of COVID-19 pneumonia, PMID: 32360420
Siltuximab: first global approval, PMID: 24958337
CAR T-Cells, PMID: 32301017
Siltuximab: a new option for the management of Castleman's disease, PMID: 25685858
Siltuximab (CNTO 328): a promising option for human malignancies, PMID: 26170629
Siltuximab (Sylvant) for treatment of multicentric castleman's disease, PMID: 25555075
Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease, PMID: 26634298
FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease, PMID: 25601959
Population pharmacokinetics of siltuximab: impact of disease state, PMID: 31482226
Review of siltuximab in the treatment of multicentric Castleman's disease, PMID: 27904739
COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study, PMID: 32593339
Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report, PMID: 32564425
The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease, PMID: 32088937
Treatment of Idiopathic Castleman Disease, PMID: 29157622
Interleukin-6 as a therapeutic target, PMID: 25589616
Siltuximab (Sylvant). Castleman's disease: good symptomatic efficacy in some patients, PMID: 27152394
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program, PMID: 30074630
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma, PMID: 30890552
Interleukin-6: A Masterplayer in the Cytokine Network, PMID: 31958792
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review, PMID: 33068263
Emerging agents and regimens for multiple myeloma, PMID: 33168044
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers, PMID: 24076269
Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma, PMID: 33091158
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease, PMID: 30181172
Diagnosis and Management of Castleman Disease, PMID: 31766018
Dose selection of siltuximab for multicentric Castleman's disease, PMID: 25784388
Emerging treatments in Castleman disease - a critical appraisal of siltuximab, PMID: 26869762
Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease, PMID: 30487129
Role of monoclonal antibody drugs in the treatment of COVID-19, PMID: 33083387
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab, PMID: 33128769
Siltuximab for multicentric Castleman disease, PMID: 25110138
Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma, PMID: 27654928
[Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer], PMID: 21211286
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer, PMID: 30372844
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors), PMID: 29447987
Effect of siltuximab, omalizumab, infliximab, pembrolizumab and vedolizumab on selected haematological and biochemical parameters in a pig model, PMID: 32233286
Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities, PMID: 28707587
Interleukin-6 inhibition in the management of non-infectious uveitis and beyond, PMID: 31523783
Siltuximab in transplant-ineligible patients with myeloma, PMID: 25121174
For research use only. Not for human or drug use.
